Age at Growth Hormone Therapy Start and First-Year Responsiveness to Growth Hormone Are Major Determinants of Height Outcome in Idiopathic Short Stature

2007113 citationsJournal Article

Authors

Michael B. Ranke · University Children's Hospital Tübingen

Anders Lindberg · Pfizer (Sweden)

David A. Price · St Mary's Hospital

Feyza Darendelıler · Istanbul University

Kerstin Albertsson‐Wikland · Sahlgrenska University Hospital

Patrick Wilton · Pfizer (United States)

Edward O. Reiter

Abstract

Prepubertal children with ISS who show an appropriate first-year response to GH are likely to benefit from long-term treatment, even on low GH dosages.

Topics & Keywords

Growth Hormone and Insulin-like Growth Factors Lipid metabolism and disorders Pituitary Gland Disorders and Treatments

Publication Details

Published in: Hormone Research in Paediatrics

Volume 68, Issue 2, pp. 53-62

DOI: 10.1159/000098707

Field-Weighted Citation Impact: 5.00

Command Palette

Age at Growth Hormone Therapy Start and First-Year Responsiveness to Growth Hormone Are Major Determinants of Height Outcome in Idiopathic Short Stature

Authors

Abstract

Topics & Keywords

Publication Details